Bio Plus Co

Bio Plus Co Acquisitions (Net)

The Acquisitions (Net) of Bio Plus Co (099430.KQ) as of Oct 22, 2026 is 12.28 B KRW. In the previous year, Acquisitions (Net) was 43.30 B KRW — a change of -71.63% (lower).

Acquisitions (Net)

12.28 BKRW

YoY

-71.63%

Last updated:

Acquisitions (Net) of Bio Plus Co is 2024 12.28 B KRW. Acquisitions (Net) of Bio Plus Co was 2023 43.30 B KRW. It decreases by -71.63% lower compared to the previous year.

The Bio Plus Co Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
-1.13 B KRW
Jan 1, 2019
1.10 B KRW
Jan 1, 2020
-480.91 M KRW
Jan 1, 2021
-7.28 B KRW
Jan 1, 2022
-60.44 B KRW
Jan 1, 2023
43.30 B KRW
Jan 1, 2024
12.28 B KRW
The Bio Plus Co Acquisitions (Net) history
YEARAcquisitions (Net)YoY
12.28 BKRW-71.63%
43.30 BKRW-171.65%
-60.44 BKRW+730.56%
-7.28 BKRW+1,413.08%
-480.91 MKRW-143.67%
1.10 BKRW-197.43%
-1.13 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio Plus Co Stock analysis

What does Bio Plus Co do? BioPlus Co., Ltd. generates revenue through the manufacturing and sale of dermal fillers, primarily hyaluronic acid fillers for temporary facial wrinkle improvement. The company also produces and sells anti-adhesion agents to prevent surgical adhesions, biomaterials for joint tissue repair, and other tissue restoration products. These products are supplied to medical professionals and healthcare facilities requiring cosmetic and surgical solutions. The firm targets the medical and cosmetic sectors, focusing on tissue restoration applications for both aesthetic and functional needs. The company's product portfolio includes biomaterials for tissue restoration, specifically designed for temporary facial wrinkle correction, anti-adhesion solutions for surgical sites, and joint tissue repair materials. These offerings cater to healthcare providers seeking advanced biomaterials for patient care. BioPlus Co., Ltd. serves the medical industry by providing specialized products that address both cosmetic enhancement and post-surgical recovery requirements. BioPlus Co., Ltd. operates within the biomaterials sector, focusing on dermal fillers and tissue repair solutions. Its products are utilized by medical practitioners for facial aesthetics and surgical applications. The company's revenue streams are derived from direct sales of these biomaterial products to healthcare institutions and professionals in the medical field. Bio Plus Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio Plus Co stock

Acquisitions (Net) of Bio Plus Co is 12.28 B KRW in 2024.

Acquisitions (Net) of Bio Plus Co changed from 43.30 B KRW to 12.28 B KRW, representing a -71.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Bio Plus Co since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Bio Plus Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bio Plus Co

All Key Metrics — Bio Plus Co